At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 215 enrolled
Drug / intervention
Lusutrombopag +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Randomised, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of S-888711 (Lusutrombopag) for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures (L-PLUS 2)
In Brief
A Phase 3 clinical trial evaluating Lusutrombopag and Placebo for Chronic Liver Disease and Thrombocytopenia. Completed, enrolled 215 participants.
Detailed Summary
The primary purpose of this study is to compare the efficacy of lusutrombopag with placebo for the treatment of thrombocytopenia in patients with chronic liver disease who are undergoing elective invasive procedures.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Liver Disease, Thrombocytopenia
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 2015
Enrollment StartJun 2015
Primary CompletionApr 2017
Study CompletionApr 2017
TodayJul 2026
First PostedMar 17, 2015
Enrollment StartJun 15, 2015
Primary CompletionApr 5, 2017
Study CompletionApr 19, 2017
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 11.3 years ago
Interventions
Lusutrombopagdrug
Tablets for oral administration
Placebodrug
Tablets for oral administration